Summary of Gilead Sciences Conference Call Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Date of Conference**: November 10, 2025 Key Industry Insights - **Policy Environment**: Ongoing discussions with the U.S. administration regarding Medicaid and pricing disparities between the U.S. and Europe, with a focus on maintaining innovation in the biotech sector [6][7][8] - **R&D Commitment**: Gilead has committed $32 billion to U.S. R&D and manufacturing investments over the next five years [8] Core Business Segments HIV Business - **Market Position**: Gilead has the largest HIV treatment and prevention business, with a projected 5% growth in 2025 despite headwinds from Medicare Part D reforms [12][23] - **Yeztugo Launch**: Yeztugo, a new long-acting HIV prevention injection, generated $39 million in sales in Q3 and is expected to reach $150 million for the year [15][17] - **Access and Adoption**: Over 75% access to covered lives in the U.S. achieved within three months of launch, with major Medicaid plans including Yeztugo on their formularies [17][22] - **Descovy Performance**: Descovy, the existing daily pill for HIV prevention, grew 32% year-over-year, contributing significantly to the overall HIV prevention business growth of 42% [14][26] Oncology and Liver Disease - **Livdelzi Performance**: Livdelzi, a drug for primary biliary cholangitis, achieved $105 million in sales with a 35% quarter-over-quarter growth, partly due to the withdrawal of a competitor's product [42][44] - **Hepcludex Update**: Hepcludex for hepatitis D is expected to be refiled in the U.S. after successful performance in Europe, representing a growth opportunity in Gilead's liver portfolio [50][52] Cell Therapy - **Anito-cel Development**: Anito-cel, a BCMA cell therapy for multiple myeloma, is expected to launch in 2026, with potential for significant market share [55][56] - **Trodelvy Growth**: Trodelvy is projected to grow significantly as it moves into first-line treatment for triple-negative breast cancer, with a current run rate of approximately $1.4 billion [58][59] Financial Performance and Guidance - **Sales Growth**: Gilead's overall business is experiencing strong growth, particularly in HIV prevention and treatment, with a robust pipeline of new products [11][12][52] - **Capital Allocation Strategy**: Gilead plans to remain active in business development but will be selective due to a strong existing portfolio and no immediate patent cliffs until 2036 [65][68] Additional Considerations - **Market Dynamics**: Gilead is observing competitive pressures in the cell therapy market but remains committed to expanding its offerings [56][57] - **Therapeutic Focus**: The company will continue to focus on virology, liver disease, inflammation, and oncology, with no immediate plans to enter new therapeutic areas [70][71] This summary encapsulates the key points discussed during the conference call, highlighting Gilead Sciences' strategic direction, market performance, and future growth opportunities.